CRUK | Policy | NICE decision on Abiraterone

The National Institute of Health and Clinical Excellence (NICE) has given a preliminary 'no' to a prostate cancer drug that we helped develop, because it's too expensive. Professor Peter Johnson, Cancer Research UK's chief clinician, calls for a solution to be found so that the drug which offers valuable extra months to men with advanced prostate cancer, can be approved.
There's more information about this story on our blog: http://bit.ly/zCw0g9